论文部分内容阅读
本实验研究MAGE3-HLA-A2肽疫苗诱导胃癌特异性CTL的杀伤作用,及免疫治疗的可行性.选择HLA血清学分型试剂盒购自(中日友好医院),RT-PCR试剂盒购自日本TAKARA公司,MAGE3引物序列由日本TAKARA公司合成,41例胃癌患者来自本院腹部外科,血细胞分离仪采用CS3000PLUS.MTT试剂盒(德国宝灵曼公司),靶细胞系Mel-526(表达MAGE3-HLA-A2)由Mr.Dr TaKesako惠赠,用胃癌患者外周血5ml采用血清学方法检测HLA-A分型,筛选HLA-A2阳性患者留取新鲜胃癌手术标本1cm~3,RT-PCR方法检测MACF3表达,MACE3/HLA-A2阳性患者经CS-3000PLUS采集单个核细胞,GM-CSF+IL4诱导DC7d,流式细胞仪检测
This study was designed to investigate the killing effect of the MAGE3-HLA-A2 peptide vaccine on gastric cancer-specific CTLs and the feasibility of immunotherapy. The HLA serological typing kit was purchased from China-Japan Friendship Hospital and the RT-PCR kit was purchased from Japan. TAKARA, MAGE3 primer sequence was synthesized by TAKARA, Japan. Forty-one patients with gastric cancer came from our department’s abdominal surgery. The blood cell separator used the CS3000PLUS.MTT kit (Berlinger, Germany) and the target cell line Mel-526 (expressed MAGE3-HLA). -A2) Written by Mr. Dr Ta Kesako, 5 ml of peripheral blood of gastric cancer patients were tested for HLA-A genotyping by serological methods. HLA-A2 positive patients were selected for fresh gastric cancer specimens with a size of 1 cm~3, and MACF3 expression was detected by RT-PCR. , MACE3/HLA-A2 positive patients were collected by CS-3000PLUS mononuclear cells, GM-CSF + IL4 induced DC7d, flow cytometry